The easy explanation is the new strong buy rating. While it is nice to se the stock up I would have like to see the "news" about the LLY filing a patent application, play out. Even with all the caveats, no combo trial, no test on humans by LLY, not a patent just an application, this remains IMO a significant event. LLY is a great company, and any interest shown by them, is of some interest, and worth something to XOMA.
AGN, is also, IMO a very interesting company. They like the antibiotic resistant potential of BPI, and of course BAX is interested in the I.V. side.
Again by some calculations it is about time for BAX/XOMA to take Neuprex into clinic for another indication. When this happens, it is possible, that we will learn more about the BAX/XOMA agreement. To me this is as important as the indication itself. |
